LOS ANGELES, Sept. 24, 2018 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP (“GPM”) reminds investors of the September 25,
2018 deadline to file a lead plaintiff motion in the class action filed on behalf of investors that purchased Tetraphase
Pharmaceuticals, Inc. (“Tetraphase” or the “Company”) (NASDAQ: TTPH) securities pursuant and/or traceable to the Company’s allegedly false and/or misleading
registration statement and prospectus issued in connection with the Company’s July 2017 secondary public offering (“SPO” or the
“Offering”); and/or, acquired Tetraphase securities between March 8, 2017 and February 13, 2018, inclusive
(the “Class Period”). Tetraphase investors have until September 25, 2018 to file a lead plaintiff
motion.
If you are a shareholder who suffered a loss, click here to participate.
The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false
and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and
prospects. Specifically, Defendants failed to disclose: (1) Tetraphase was increasing the patient enrollment in its IGNITE3 trial
from 1,000 patients to 1,200 patients to meet the trial’s primary endpoints (within the 10% non-inferiority margin); (2) The
enrollment of more patients in the trial indicated that the existing population was inadequate to meet the trial’s primary
endpoints; and (3) that, as a result of the foregoing, Defendants’ statements about Tetraphase’s business, operations, and
prospects, were materially false and/or misleading and/or lacked a reasonable basis.
Follow us for updates on Twitter: twitter.com/GPM_LLP.
If you purchased shares Tetraphase during the Class Period you may move the Court no later
than September 25, 2018 to ask the Court to appoint you as lead. To be a member of the Class you need
not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the Class.
If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or
interests with respect to these matters, please contact Lesley Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los
Angeles California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to shareholders@glancylaw.com, or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number
and number of shares purchased.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and
ethical rules.
Contacts
Glancy Prongay and Murray LLP, Los Angeles
Lesley Portnoy, 310-201-9150 or 888-773-9224
www.glancylaw.com
shareholders@glancylaw.com